17:32 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

FDA approves Leadiant therapy for ADA-SCID

Leadiant Biosciences Inc. said FDA approved Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency. Approval of the pegylated recombinant adenosine deaminase enzyme replacement therapy is based on two...
19:56 , Oct 8, 2018 |  BC Extra  |  Company News

FDA approves Leadiant therapy for ADA-SCID

Leadiant Biosciences Inc. said FDA approved Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency. Approval of the pegylated recombinant adenosine deaminase enzyme replacement therapy is based on two...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Sigma-Tau sales and marketing update

Sigma-Tau expanded its patient assistance program for severe combined immunodeficiency disease (SCID) drug Adagen to include a co-pay assistance program in the U.S. The program will cover 100% of any out-of-pocket patient costs associated with...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

Enzon, Sigma-Tau S.p.A. deal

Sigma-Tau, which said the deal will increase its presence in the field of rare diseases, also will acquire Enzon's Indianapolis, Ind. manufacturing facility. Goldman Sachs and Greenhill advised Enzon. The deal is expected to close...
08:00 , Nov 16, 2009 |  BioCentury  |  Strategy

Leftovers in Enzon's refrigerator

Now that activist shareholders have won their two-year battle to restructure Enzon Pharmaceuticals Inc. , the question is what will happen to the development stage assets that remain. Last week, the company announced it will...
01:15 , Nov 10, 2009 |  BC Extra  |  Top Story

Enzon to sell specialty pharma business

Sigma-Tau S.p.A. (Rome, Italy) will acquire the specialty pharmaceuticals business of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) for $300 million in cash and up to $27 million in potential milestones. The deal includes four marketed products: antifungal...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Enzon drug delivery, infectious, cancer news

Knott Partners, which owns about 4% of Enzon, sent a letter to CEO Jeffery Buchalter and the board suggesting immediate action, including a share buyback plan; an auction for the entire company or its specialty...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Enzon drug delivery, infectious, cancer news

Enzon will explore strategic alternatives for its specialty pharmaceutical business while the company continues to pursue a plan to spin out its biotech business. Alternatives the company is considering include selling the entire specialty pharma...
01:20 , Aug 12, 2008 |  BC Extra  |  Company News

Enzon seeking alternatives for specialty pharma unit

Enzon (NASDAQ:ENZN) said it is exploring strategic alternatives for its specialty pharmaceutical business even as the company continues to pursue a plan to spin out its biotech business. The company said the alternatives it is...
07:00 , Mar 17, 2008 |  BioCentury  |  Finance

Ebb & Flow

Amgen...